Enlivex leverages debt to bulk up RAIN holdings, approves $20M buyback
Immunotherapy developer Enlivex said it has raised $21 million in debt financing and used part of the proceeds to expand a treasury built around Rain (RAIN), a prediction-market token. The New York asset manager The Lind Partners provided the capital as Enlivex pursues a strategy of holding tokenized assets alongside its biotech operations.
Key moves and numbers
- Debt financing raised: $21 million from The Lind Partners.
- Immediate RAIN purchase: exercised an option to buy 3 billion RAIN for $10 million — about $0.00333 per token, which the company said represented a ~62% discount to prevailing prices.
- Extended option: Enlivex extended its right to acquire another 272.1 billion RAIN at the same price through December 2027.
- Share buyback: the company also approved a $20 million share-repurchase program aimed at supporting shareholder value.
Why Enlivex is buying tokens
Enlivex says the funding will support its operating plan and allow it to increase exposure to Rain as part of a “prediction markets treasury strategy.” Executive chair Shai Novik said the Lind financing “provided us with substantial capital, allowing us to continue the execution of our operating plan, as well as to acquire approximately three billion additional RAIN tokens.”
About Rain and the token economics
Rain is a decentralized prediction market protocol built on Arbitrum (an Ethereum layer-2). The protocol charges a 2.5% fee on market activity and uses those fees to buy back and burn RAIN, a design intended to tie token demand to platform usage and reduce circulating supply. DeFiLlama places Rain among the top 10 prediction market platforms by total value locked and fees over the past seven days.
Market context and reaction
- Prediction markets have seen explosive growth: trading volume jumped more than 1,200% to $23.3 billion between February 2025 and February 2026.
- RAIN price reaction: the token climbed roughly 7% after Enlivex’s announcement to a peak near $0.009, later easing to about $0.0088; CoinGecko showed it up 0.3% over the previous 24 hours at the time of reporting.
- Enlivex equity: the company’s shares were down 0.9% to $1.10 at the Tuesday close, then rose 4.5% in after-hours trading to $1.15.
Broader significance
Enlivex is best known for developing cell-therapy products for knee osteoarthritis, but its moves reflect a growing trend of non-crypto companies adding digital assets to corporate treasuries. By buying discounted RAIN and extending purchase options, Enlivex is effectively using crypto exposure as part of a broader capital and treasury strategy — a bet that usage-driven token economics (buyback + burn) and prediction-market growth can create upside for holders.
A final note: while Rain is gaining traction among smaller prediction-market platforms, Kalshi and Polymarket still dominate the sector, accounting for more than 80% of total trading volume.
Read more AI-generated news on: undefined/news
